SG11201906980YA - Intranasal composition comprising betahistine - Google Patents
Intranasal composition comprising betahistineInfo
- Publication number
- SG11201906980YA SG11201906980YA SG11201906980YA SG11201906980YA SG11201906980YA SG 11201906980Y A SG11201906980Y A SG 11201906980YA SG 11201906980Y A SG11201906980Y A SG 11201906980YA SG 11201906980Y A SG11201906980Y A SG 11201906980YA SG 11201906980Y A SG11201906980Y A SG 11201906980YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- betahistine
- intranasal
- pct
- english
- Prior art date
Links
- UUQMNUMQCIQDMZ-UHFFFAOYSA-N betahistine Chemical compound CNCCC1=CC=CC=N1 UUQMNUMQCIQDMZ-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004536 betahistine Drugs 0.000 title abstract 4
- 239000000203 mixture Substances 0.000 title abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 240000006409 Acacia auriculiformis Species 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- 239000013543 active substance Substances 0.000 abstract 1
- 210000005069 ears Anatomy 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102220240796 rs553605556 Human genes 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Abstract
v • c • 8000 Q 0 C .17g' C 6000 „9 [13 C CO • rj 2000 0 4000 14000 12000 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 09 August 2018 (09.08.2018) WIP0 I PCT °Ens °nolo olo mimiciolomoiliflo (10) International Publication Number WO 2018/141922 Al (51) International Patent Classification: A61K 31/4402 (2006.01) A61K 47/32 (2006.01) A61P 27/16 (2006.01) A61K 9/08 (2006.01) (21) International Application Number: PCT/EP2018/052695 (22) International Filing Date: 02 February 2018 (02.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/453,931 02 February 2017 (02.02.2017) US (71) Applicant: OTOLANUM AG [CH/CH]; c/o Auris Med- ical Holding AG, Bahnhofstrasse 21, CH-6300 Zug (CH). (72) Inventors: WRAIGHT, Christopher John; 25 Eustace Street, Blackburn, Victoria 3130 (AU). MEYER, Thomas; Birkenweg 6, 4528 Zuchwil (CH). (74) Agent: COOLEY (UK) LLP; COWLEY, Catherine, Dashwood, 69 Old Broad Street, London Greater London, EC2M 1QS (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 2 I (3)) (54) Title: INTRANASAL COMPOSITION COMPRISING BETAHISTINE FIG. 3 5 mg 10 mg 20 mg 40 mg Intranasal betahistine dose 1-1 © (57) : The present disclosure relates to a pharmaceutical composition comprising as active substance betahistine or a phar- maceutically acceptable salt thereof, for use in the treatment of otological or neurological disorders in a human subject by intranasal C application.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762453931P | 2017-02-02 | 2017-02-02 | |
| PCT/EP2018/052695 WO2018141922A1 (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201906980YA true SG11201906980YA (en) | 2019-08-27 |
Family
ID=61187302
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906980YA SG11201906980YA (en) | 2017-02-02 | 2018-02-02 | Intranasal composition comprising betahistine |
Country Status (34)
| Country | Link |
|---|---|
| US (2) | US10456386B2 (en) |
| EP (2) | EP3474850B1 (en) |
| JP (3) | JP2020506930A (en) |
| KR (1) | KR102653545B1 (en) |
| CN (1) | CN110418643A (en) |
| AR (1) | AR111699A1 (en) |
| AU (1) | AU2018216970B2 (en) |
| BR (1) | BR112019015687A2 (en) |
| CA (1) | CA3051725A1 (en) |
| CL (1) | CL2019002145A1 (en) |
| CO (1) | CO2019008657A2 (en) |
| DK (2) | DK3474850T3 (en) |
| EA (1) | EA201991817A1 (en) |
| ES (1) | ES2807798T3 (en) |
| FI (1) | FI3698791T3 (en) |
| HR (2) | HRP20231706T1 (en) |
| HU (1) | HUE050829T2 (en) |
| IL (1) | IL268353B2 (en) |
| LT (2) | LT3698791T (en) |
| MA (1) | MA46778B1 (en) |
| MX (1) | MX2019008961A (en) |
| MY (1) | MY196333A (en) |
| NZ (1) | NZ755931A (en) |
| PH (1) | PH12019501785A1 (en) |
| PL (2) | PL3474850T3 (en) |
| PT (2) | PT3474850T (en) |
| RS (2) | RS65099B1 (en) |
| SA (1) | SA519402324B1 (en) |
| SG (1) | SG11201906980YA (en) |
| SI (1) | SI3474850T1 (en) |
| TN (1) | TN2019000220A1 (en) |
| TW (1) | TWI760429B (en) |
| WO (1) | WO2018141922A1 (en) |
| ZA (1) | ZA201904955B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018170532A1 (en) * | 2017-03-22 | 2018-09-27 | Franz, Lilian Ann | Treatment method |
| US20230338279A1 (en) * | 2020-04-14 | 2023-10-26 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Nasal spray formulation with moisturizing benefits |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2397840B1 (en) | 1977-07-22 | 1981-03-20 | Cherqui Jean | |
| IT1229237B (en) * | 1989-05-08 | 1991-07-26 | Prodotti Formenti | SALTS OF (2- (PYRIDYL) ETHYL) METHYLAMINE |
| JPH03287535A (en) * | 1990-03-31 | 1991-12-18 | Bairon Boeki Kk | Aqueous solution of pranoprofen |
| JP3203056B2 (en) * | 1992-08-13 | 2001-08-27 | 株式会社ティ・ティ・エス技術研究所 | Composition for transdermal absorption preparation of betahistine mesylate and transdermal absorption preparation |
| US5897858A (en) * | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| JPH10139667A (en) * | 1996-11-15 | 1998-05-26 | Yoshitomi Pharmaceut Ind Ltd | Aqueous liquid agent |
| JP2005503425A (en) | 2001-05-24 | 2005-02-03 | アレックザ モレキュラー デリヴァリー コーポレイション | Delivery of drug ester by the prescribed inhalation route |
| US7090830B2 (en) | 2001-05-24 | 2006-08-15 | Alexza Pharmaceuticals, Inc. | Drug condensation aerosols and kits |
| JP3555598B2 (en) | 2001-06-27 | 2004-08-18 | 株式会社村田製作所 | Multilayer inductor |
| JP2004196676A (en) * | 2002-12-16 | 2004-07-15 | Rohto Pharmaceut Co Ltd | Nasal drop |
| JP4733333B2 (en) * | 2002-12-26 | 2011-07-27 | ライオン株式会社 | Nasal or nasal rinse |
| ATE319426T1 (en) | 2003-11-11 | 2006-03-15 | Mattern Udo | NASAL FORMULATION WITH CONTROLLED RELEASE OF SEXUAL HORMONES |
| US7728015B2 (en) * | 2004-04-22 | 2010-06-01 | Mor Research Applications Ltd. | Compositions for weight management |
| EA200601414A1 (en) * | 2004-04-22 | 2007-02-27 | Мор Рисерч Эппликейшнз Лтд. | METHOD OF CONTROL OF FOOD CONSUMPTION |
| AU2006202950A1 (en) * | 2004-04-22 | 2006-10-19 | Mor Research Applications Ltd. | Methods and Compositions for Weight Management |
| EP1789075A4 (en) | 2004-08-25 | 2009-07-01 | Uab Research Foundation | Absorption enhancers for drug administration |
| US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
| US20070111964A1 (en) * | 2005-08-17 | 2007-05-17 | Fleming And Company, Pharmaceuticals | Vitamin B12 nasal spray and method of use |
| US8119668B2 (en) | 2005-12-23 | 2012-02-21 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| US8242148B2 (en) * | 2005-12-23 | 2012-08-14 | Nelson Erik B | Treatment methods employing histamine H3 receptor antagonists, including betahistine |
| US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
| BRPI0821647A2 (en) * | 2007-12-21 | 2015-06-16 | Schering Plough Healthcare | Enhancement of oxymetazoline photo stabilization |
| WO2009132050A2 (en) * | 2008-04-21 | 2009-10-29 | Otonomy, Inc. | Auris formulations for treating otic diseases and conditions |
| NZ589742A (en) | 2008-05-27 | 2012-06-29 | Univ Melbourne | Methods of treating mammals with eustachian tube dysfunctions with betahistine |
| US8268887B2 (en) * | 2008-10-08 | 2012-09-18 | Feng Xu | Drug conjugates and methods of use thereof |
| US10471040B2 (en) * | 2014-10-03 | 2019-11-12 | Lachesis Biosciences Limited | Intranasal compositions for treatment of neurological and neurodegenerative diseases and disorders |
-
2018
- 2018-02-02 FI FIEP20170448.3T patent/FI3698791T3/en active
- 2018-02-02 PL PL18703749T patent/PL3474850T3/en unknown
- 2018-02-02 DK DK18703749.4T patent/DK3474850T3/en active
- 2018-02-02 NZ NZ755931A patent/NZ755931A/en unknown
- 2018-02-02 EA EA201991817A patent/EA201991817A1/en unknown
- 2018-02-02 EP EP18703749.4A patent/EP3474850B1/en active Active
- 2018-02-02 DK DK20170448.3T patent/DK3698791T3/en active
- 2018-02-02 KR KR1020197025622A patent/KR102653545B1/en active IP Right Grant
- 2018-02-02 US US15/887,388 patent/US10456386B2/en active Active
- 2018-02-02 LT LTEP20170448.3T patent/LT3698791T/en unknown
- 2018-02-02 HR HRP20231706TT patent/HRP20231706T1/en unknown
- 2018-02-02 EP EP20170448.3A patent/EP3698791B1/en active Active
- 2018-02-02 BR BR112019015687A patent/BR112019015687A2/en unknown
- 2018-02-02 SI SI201830082T patent/SI3474850T1/en unknown
- 2018-02-02 SG SG11201906980YA patent/SG11201906980YA/en unknown
- 2018-02-02 PT PT187037494T patent/PT3474850T/en unknown
- 2018-02-02 PT PT201704483T patent/PT3698791T/en unknown
- 2018-02-02 CA CA3051725A patent/CA3051725A1/en active Pending
- 2018-02-02 HU HUE18703749A patent/HUE050829T2/en unknown
- 2018-02-02 JP JP2019541717A patent/JP2020506930A/en active Pending
- 2018-02-02 TN TNP/2019/000220A patent/TN2019000220A1/en unknown
- 2018-02-02 CN CN201880017726.2A patent/CN110418643A/en active Pending
- 2018-02-02 AU AU2018216970A patent/AU2018216970B2/en active Active
- 2018-02-02 RS RS20240022A patent/RS65099B1/en unknown
- 2018-02-02 ES ES18703749T patent/ES2807798T3/en active Active
- 2018-02-02 IL IL268353A patent/IL268353B2/en unknown
- 2018-02-02 LT LTEP18703749.4T patent/LT3474850T/en unknown
- 2018-02-02 MY MYPI2019004366A patent/MY196333A/en unknown
- 2018-02-02 RS RS20200851A patent/RS60554B1/en unknown
- 2018-02-02 TW TW107103800A patent/TWI760429B/en active
- 2018-02-02 MA MA46778A patent/MA46778B1/en unknown
- 2018-02-02 WO PCT/EP2018/052695 patent/WO2018141922A1/en unknown
- 2018-02-02 AR ARP180100254A patent/AR111699A1/en unknown
- 2018-02-02 MX MX2019008961A patent/MX2019008961A/en unknown
- 2018-02-02 PL PL20170448.3T patent/PL3698791T3/en unknown
-
2019
- 2019-07-26 SA SA519402324A patent/SA519402324B1/en unknown
- 2019-07-29 ZA ZA2019/04955A patent/ZA201904955B/en unknown
- 2019-07-30 CL CL2019002145A patent/CL2019002145A1/en unknown
- 2019-08-05 PH PH12019501785A patent/PH12019501785A1/en unknown
- 2019-08-09 CO CONC2019/0008657A patent/CO2019008657A2/en unknown
- 2019-09-13 US US16/570,156 patent/US20200022963A1/en not_active Abandoned
-
2020
- 2020-07-20 HR HRP20201137TT patent/HRP20201137T1/en unknown
-
2022
- 2022-02-08 JP JP2022017792A patent/JP2022051872A/en not_active Withdrawn
-
2024
- 2024-01-04 JP JP2024000158A patent/JP2024019731A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201906412SA (en) | Pyridine compounds as allosteric shp2 inhibitors | |
| SG11201903928WA (en) | Mesenchymal stem cells populations, their products, and use thereof | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201811151PA (en) | Extracellular vesicle comprising a fusion protein having fc binding capacity | |
| SG11201811148SA (en) | Cell penetrating peptide (cpp)-mediated ev loading | |
| SG11201811150WA (en) | Ev-mediated delivery of binding protein-small molecule conjugates | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201901228QA (en) | Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201811209QA (en) | Oral gastroretentive formulations and uses thereof | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201806127XA (en) | Pharmaceutical or nutritional combination comprising beta-hydroxy-betamethylbutyrate | |
| SG11201810801QA (en) | Brain delivery protein | |
| SG11201810123SA (en) | Treatment of intrahepatic cholestatic diseases |